Beese Fulmer Investment Management Inc. Purchases 12,078 Shares of Edwards Lifesciences Corporation $EW

Beese Fulmer Investment Management Inc. grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 8.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 152,746 shares of the medical research company’s stock after acquiring an additional 12,078 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Edwards Lifesciences were worth $11,879,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. True Wealth Design LLC increased its position in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the period. Hantz Financial Services Inc. raised its stake in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after purchasing an additional 164 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Finally, Strengthening Families & Communities LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $34,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: EW was named among “5 Medical Instruments Stocks to Buy” for near-term upside tied to AI-enabled tools, M&A and new product pipelines — this highlights elevated analyst/market interest in Edwards’ growth catalysts. Zacks: 5 Medical Instruments Stocks to Buy Yahoo: 5 Medical Instruments Stocks to Buy
• Positive Sentiment: Brokerage consensus cited as an average “Moderate Buy,” reinforcing analyst support that can sustain demand for the shares. American Banking News: Moderate Buy
• Positive Sentiment: Recent commentary notes EW has outperformed the S&P 500 and analysts remain moderately optimistic — a sign of relative strength vs. the market that can attract momentum buyers. Barchart: Outperforming the S&P 500
• Neutral Sentiment: Management presented at Barclays’ 28th Annual Global Healthcare Conference (transcript available) — investors should watch for any strategic commentary or forward guidance color, but no headline surprises reported yet. Seeking Alpha: Barclays Presentation Transcript
• Neutral Sentiment: Broader diagnostics and medical-device sector stories (IDXX, DGX, National Vision) point to healthy industry fundamentals and innovation, which can be a supportive backdrop for EW even if the articles aren’t specific to Edwards. Yahoo: IDEXX Yahoo: Quest Diagnostics Yahoo: National Vision
• Negative Sentiment: Short interest rose sharply in February — up ~56.6% vs. mid‑February to ~12.38M shares (about 2.1% of shares outstanding), with a short-interest ratio ~2.7 days. That increase can amplify near-term volatility and create short‑covering squeezes if catalysts reverse. (Data reported 2/27)

Analyst Ratings Changes

A number of research firms have recently weighed in on EW. Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. UBS Group reiterated a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Finally, Barclays reissued an “overweight” rating and set a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 60,104 shares of company stock valued at $5,084,637. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $85.76 on Wednesday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The stock has a market capitalization of $49.81 billion, a price-to-earnings ratio of 46.86, a price-to-earnings-growth ratio of 2.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The company’s 50 day simple moving average is $82.50 and its 200 day simple moving average is $81.52.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company earned $0.59 earnings per share. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.